Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 8512417, 7 pages
http://dx.doi.org/10.1155/2016/8512417
Research Article

Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation

1Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri I.R.C.C.S., Laboratory for Endocrine Disruptors and Chair of Endocrinology University of Pavia, 27100 Pavia, Italy
2Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman 11937, Jordan
3Allergy and Immunology Unit, Fondazione Salvatore Maugeri I.R.C.C.S., 27100 Pavia, Italy
4Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
5Biotechnology Research Laboratories, I.R.C.C.S., Policlinico San Matteo Foundation, 27100 Pavia, Italy
6Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA

Received 18 May 2016; Revised 1 July 2016; Accepted 10 July 2016

Academic Editor: Carolina T. Piñeiro

Copyright © 2016 Mario Rotondi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. J. Waugh and C. Wilson, “The interleukin-8 pathway in cancer,” Clinical Cancer Research, vol. 14, no. 21, pp. 6735–6741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Rotondi, F. Coperchini, and L. Chiovato, “CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice,” Cytokine and Growth Factor Reviews, vol. 24, no. 6, pp. 539–546, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. F. Sanmamed, O. Carranza-Rua, C. Alfaro et al., “Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins,” Clinical Cancer Research, vol. 20, no. 22, pp. 5697–5707, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Brennecke, M. Deichmann, H. Naeher, and H. Kurzen, “Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma,” Melanoma Research, vol. 15, no. 6, pp. 515–522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Broutin, N. Ameur, L. Lacroix et al., “Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models,” Clinical Cancer Research, vol. 17, no. 7, pp. 2044–2054, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Chen, J. Fan, H. Chen et al., “The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases,” Scientific Reports, vol. 4, article 5911, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Hirsch, C. L. Johnson, T. Nelius, R. Kennedy, W. D. Riese, and S. Filleur, “PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ,” Cytokine, vol. 55, no. 2, pp. 202–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. T. Bauerle, R. E. Schweppe, G. Lund et al., “Nuclear factor κb-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 8, pp. E1436–E1444, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Visciano, F. Liotti, N. Prevete et al., “Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway,” Oncogene, vol. 34, no. 40, pp. 5175–5186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Grosse, E. Warnke, F. Pohl et al., “Impact of sunitinib on human thyroid cancer cells,” Cellular Physiology and Biochemistry, vol. 32, no. 1, pp. 154–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Fang, L. Ye, L. Shen et al., “Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8,” Carcinogenesis, vol. 35, no. 8, pp. 1780–1787, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Rotondi, F. Coperchini, P. Pignatti, F. Magri, and L. Chiovato, “Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 3, pp. E427–E432, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Gales, C. Clark, U. Manne, and T. Samuel, “The chemokine CXCL8 in carcinogenesis and drug response,” ISRN Oncology, vol. 2013, Article ID 859154, 8 pages, 2013. View at Publisher · View at Google Scholar
  14. M. Muzza, D. Degl'Innocenti, C. Colombo et al., “The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies,” Clinical Endocrinology, vol. 72, no. 5, pp. 702–708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. G. Borrello, L. Alberti, A. Fischer et al., “Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 41, pp. 14825–14830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Klubo-Gwiezdzinska, J. Costello Jr., A. Patel et al., “Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. 3269–3279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Chen, S. Xu, K. Renko, and M. Derwahl, “Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. E510–E520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Coperchini, P. Leporati, M. Rotondi, and L. Chiovato, “Expanding the therapeutic spectrum of metformin: from diabetes to cancer,” Journal of Endocrinological Investigation, vol. 38, no. 10, pp. 1047–1055, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Cassatella, I. Guasparri, M. Ceska, F. Bazzoni, and F. Rossi, “Interferon-gamma inhibits interleukin-8 production by human polymorphonuclear leucocytes,” Immunology, vol. 78, no. 2, pp. 177–184, 1993. View at Google Scholar · View at Scopus
  20. S. Nozell, T. Laver, K. Patel, and E. N. Benveniste, “Mechanism of IFN-β-mediated inhibition of IL-8 gene expression in astroglioma cells,” Journal of Immunology, vol. 177, no. 2, pp. 822–830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Rotondi, F. Coperchini, R. Sideri et al., “Type I and type II interferons inhibit both basal and tumor necrosis factor-α-induced CXCL8 secretion in primary cultures of human thyrocytes,” Journal of Interferon and Cytokine Research, vol. 33, no. 9, pp. 508–513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani, “Role of chemokines in endocrine autoimmune diseases,” Endocrine Reviews, vol. 28, no. 5, pp. 492–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Ruffilli, S. M. Ferrari, M. Colaci, C. Ferri, P. Fallahi, and A. Antonelli, “IP-10 in autoimmune thyroiditis,” Hormone and Metabolic Research, vol. 46, no. 9, pp. 597–602, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Rotondi and L. Chiovato, “The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-γ inducible chemokines and their receptor,” Current Pharmaceutical Design, vol. 17, no. 29, pp. 3202–3216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Coperchini, P. Pignatti, A. Carbone et al., “TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer,” Tumor Biology, vol. 37, no. 4, pp. 5569–5575, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Di Buduo, F. Moccia, M. Battiston et al., “The importance of calcium in the regulation of megakaryocyte function,” Haematologica, vol. 99, no. 4, pp. 769–778, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Coperchini, P. Pignatti, P. Leporati et al., “Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion,” Endocrine, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Crescioli, L. Cosmi, E. Borgogni et al., “Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes,” Journal of Endocrinology, vol. 195, no. 1, pp. 145–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Lombardi, G. Cantini, T. Mello et al., “Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor α and interferon γ in human microvascular endothelium,” European Journal of Cell Biology, vol. 88, no. 12, pp. 731–742, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Rotondi, F. Coperchini, P. Pignatti et al., “Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 1, pp. 308–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Rot, E. Hub, J. Middleton et al., “Some aspects of IL-8 pathophysiology III: chemokine interaction with endothelial cells,” Journal of Leukocyte Biology, vol. 59, no. 1, pp. 39–44, 1996. View at Google Scholar · View at Scopus